{"id":7694,"date":"2023-10-31T17:58:27","date_gmt":"2023-10-31T17:58:27","guid":{"rendered":"https:\/\/infundpros.com\/news\/lexeo-therapeutics-proposes-terms-for-126-million-ipo-lxeo\/"},"modified":"2023-10-31T17:58:28","modified_gmt":"2023-10-31T17:58:28","slug":"lexeo-therapeutics-proposes-terms-for-126-million-ipo-lxeo","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=7694","title":{"rendered":"Lexeo Therapeutics Proposes Terms For $126 Million IPO (LXEO)"},"content":{"rendered":"
\n

<\/picture>
<\/figcaption><\/figure>\n<\/p>\n

A Quick Take On Lexeo Therapeutics<\/h2>\n

Lexeo Therapeutics, Inc.<\/b> (LXEO) has filed proposed terms to raise $126 million from the sale of its common stock in an IPO, according to an amended SEC registration statement.<\/span><\/p>\n

The company is developing treatments for various cardiovascular and Alzheimer’s conditions.<\/p>\n

Given the firm\u2019s early stage of development, legal risks and a difficult IPO performance environment for biopharma companies, my outlook on the Lexeo Therapeutics, Inc. IPO is to Sell [Avoid].<\/p>\n

Lexeo Therapeutics Overview<\/h2>\n

New York, NY-based Lexeo Therapeutics, Inc. is developing drug treatment candidates for various cardiovascular and neurological diseases.<\/p>\n

Management is headed by Chief Executive Officer R. Nolan Townsend, who has been with the firm since 2020 and was previously at Pfizer, where he was President, Pfizer Rare Disease for the North America region.<\/p>\n

The firm’s lead candidate, LX2006, is currently in Phase 1\/2 clinical trials for the treatment of Friedreich’s ataxia.<\/span><\/p>\n

Friedreich\u2019s ataxia is characterized by the progressive loss of coordination and balance (ataxia) from the degeneration of the spinal cord and related nerves.<\/p>\n

The company expects to report interim data from the LX2006 trial in mid-2024.<\/p>\n

Below is the current status of the company\u2019s drug development pipeline:<\/p>\n

\n

\"Pipeline\" <\/picture>
\n

SEC<\/span><\/p>\n<\/figcaption><\/figure>\n<\/p>\n

Lexeo has booked fair market value investment of $189 million as of June 30, 2023, from investors, including D1, PBM LEX Holdings, Janus Henderson, Longitude Venture Partners, Lundbeckfond Invest, Eventide Healthcare & Life Sciences Fund, Omega Fund and Ronald G. Crystal, MD and affiliates.<\/p>\n

Lexeo\u2019s Market & Competition<\/h2>\n

According to a 2022 market research report by Coherent Market Insights, the global market for treatments for Freidreich’s ataxia was an estimated $777 million in 2022 and is forecast to reach $2.06 billion in 2030.<\/p>\n

This represents an expected CAGR (Compound Annual Growth Rate) of CAGR of 13.0% from 2022 to 2030.<\/p>\n

The major reasons driving this expected growth are the continued development of approved treatment options along with inorganic business collaborations and acquisitions.<\/p>\n

Also, the North American region is expected to hold the largest demand for treatments during the forecast period through 2030.<\/p>\n

The company is pursuing drug treatment activities for other multi-billion dollar size markets.<\/p>\n

Major competitive vendors that provide or are developing related treatments include:<\/p>\n